CA2624707A1 - Method for selectively depleting hypoxic cells - Google Patents

Method for selectively depleting hypoxic cells Download PDF

Info

Publication number
CA2624707A1
CA2624707A1 CA002624707A CA2624707A CA2624707A1 CA 2624707 A1 CA2624707 A1 CA 2624707A1 CA 002624707 A CA002624707 A CA 002624707A CA 2624707 A CA2624707 A CA 2624707A CA 2624707 A1 CA2624707 A1 CA 2624707A1
Authority
CA
Canada
Prior art keywords
cells
agent
bone marrow
subject
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002624707A
Other languages
English (en)
French (fr)
Inventor
Kalindi Pamar
Peter Mauch
Julian Down
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Bluebird Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2624707A1 publication Critical patent/CA2624707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002624707A 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells Abandoned CA2624707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72318305P 2005-10-03 2005-10-03
US60/723,183 2005-10-03
PCT/US2006/038553 WO2007041546A2 (en) 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells

Publications (1)

Publication Number Publication Date
CA2624707A1 true CA2624707A1 (en) 2007-04-12

Family

ID=37826084

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002624707A Abandoned CA2624707A1 (en) 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells

Country Status (5)

Country Link
US (1) US20090136521A1 (cg-RX-API-DMAC7.html)
EP (1) EP1931769A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009510165A (cg-RX-API-DMAC7.html)
CA (1) CA2624707A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007041546A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
WO2008033039A1 (en) * 2006-09-11 2008-03-20 Adam Vorn Patterson Cancer treatment
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
CA2706378C (en) 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法
ES2884674T3 (es) * 2008-10-21 2021-12-10 Immunogenesis Inc Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed
WO2010132771A1 (en) 2009-05-15 2010-11-18 Lankenau Institute For Medical Research Methods and kits for measuring toxicity and oxidative stress in live cells
US8269197B2 (en) 2009-07-22 2012-09-18 Intraop Medical Corporation Method and system for electron beam applications
CN102933258A (zh) 2010-03-01 2013-02-13 因特奥普医药公司 与含氧量低的细胞敏化剂联用的放疗
MX2012014428A (es) 2010-07-12 2013-03-05 Threshold Pharmaceuticals Inc Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
JP2015500885A (ja) 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2015013448A1 (en) 2013-07-26 2015-01-29 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794742A (fr) * 1972-02-01 1973-07-30 Bayer Ag Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition
US3957779A (en) * 1972-11-15 1976-05-18 Bayer Aktiengesellschaft Benzo-1,2,4-triazines
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
DK1014990T3 (da) * 1997-03-07 2006-12-11 Sanofi Aventis Us Llc Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強

Also Published As

Publication number Publication date
WO2007041546A3 (en) 2007-07-12
US20090136521A1 (en) 2009-05-28
EP1931769A2 (en) 2008-06-18
JP2009510165A (ja) 2009-03-12
WO2007041546A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
Neben et al. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor
Bonnet et al. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice
US20090136521A1 (en) Method for Selectively Depleting Hypoxic Cells
Chen et al. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation
DE60302231T2 (de) Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung
US9545427B2 (en) Therapeutic uses of allogeneic myeloid progenitor cells
Szilvassy et al. Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells
Kim et al. Stress-associated erythropoiesis initiation is regulated by type 1 conventional dendritic cells
US12415987B2 (en) Methods and composition for producing and using immune cells and stem cells for cell-based therapies
EP3068875B1 (en) Post-natal hematopoietic endothelial cells and their isolation and use
Stiff et al. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia
KR20220123194A (ko) 항암 활성이 증가된 자연살해세포 및 그의 면역 치료 용도
Scheffold et al. Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells
US20060140912A9 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients
Skinner et al. CXCR4 induction in hematopoietic progenitor cells from Fanca−/−,-c−/−, and-d2−/− mice
EP4516807A1 (en) Compositions for use in a method of providing improved hematopoietic stem cell engraftment
Ozkaynak et al. In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide
Neben et al. Mobilization of hematopoietic stem and progenitor cell
Zhao Characterization of cellular dynamics during bone marrow regeneration in normal and leukemic states
Storb 1Hematopoietic Stem Cell Transplantation: Yesterday, Today and Tomorrow
Yeoh et al. Mobilized peripheral blood stem cells provide rapid reconstitution but impaired long-term engraftment
Thaunat et al. IGG-MEDIATED HYDROLYSIS OF COAGULATION FACTORS IS ASSOCIATED WITH A REDUCED RISK OF CHRONIC ALLOGRAFT NEPHROPATHY IN RENAL TRANSPLANTED PATIENTS: 1510
Baumann et al. THE FISHER-LEWIS KIDNEY TRANSPLANTATION MODEL AS TOOL TO INVESTIGATE TRANSPLANT-RELATED CARDIOMYOPATHY: 1508
Hüser et al. REQUIREMENT OF LFA-1 DE-ACTIVATION FOR CARDIAC ALLOGRAFT REJECTION: 1509
Kucia et al. Hematopoietic stem cells from NOD mice exhibit autonomous behavior and

Legal Events

Date Code Title Description
FZDE Discontinued